Ionizing Radiation Promotes Expansion of a p90RSK-Activated Subset of Patrolling Monocytes: Influence of Colchicine
Clinical Scorecard: Ionizing Radiation Promotes Expansion of a p90RSK-Activated Subset of Patrolling Monocytes: Influence of Colchicine
At a Glance
Category Detail
Condition Radiation-induced cardiovascular disease (RICVD) and immune remodeling post-ionizing radiation Key Mechanisms Ionizing radiation induces expansion of CD14−CD16+CD68hi patrolling monocytes with elevated p90RSK activation and reduced CHIP-associated proteins (DNMT3A, TET2); colchicine selectively inhibits this expansion by modulating p90RSK-driven signaling Target Population Cancer survivors exposed to thoracic radiation therapy and healthy individuals exposed to ionizing radiation in vitro Care Setting Oncology and cardiovascular care settings, particularly in post-radiotherapy monitoring and management
Key Highlights
Ionizing radiation increases p90RSK activation specifically in CD14−CD16+CD68hi patrolling monocytes, leading to their expansion. Colchicine suppresses the radiation-induced expansion of this monocyte subset without restoring CHIP-associated protein expression. Colchicine’s modulation of p90RSK signaling suggests a novel mechanism to mitigate radiation-induced vascular inflammation and cardiovascular risk. Guideline-Based Recommendations
Diagnosis
Monitor immune cell subsets, particularly CD14−CD16+CD68hi monocytes, in patients exposed to ionizing radiation. Assess activation of p90RSK and expression of CHIP-associated proteins (DNMT3A, TET2) in monocytes to evaluate radiation-induced immune remodeling. Management
Consider colchicine as a potential therapeutic agent to inhibit expansion of p90RSK-activated patrolling monocytes post-radiation exposure. Incorporate colchicine alongside standard cardiovascular risk management in cancer survivors with prior thoracic radiation. Monitoring & Follow-up
Regularly evaluate cardiovascular risk markers and inflammatory profiles in cancer survivors post-radiotherapy. Monitor monocyte subset dynamics and p90RSK activation status during colchicine treatment. Risks
Recognize increased cardiovascular disease risk in patients receiving thoracic radiation, especially with elevated p90RSK-activated monocytes. Be aware that colchicine modulates immune signaling pathways without restoring CHIP protein expression, necessitating further clinical evaluation. Patient & Prescribing Data
Cancer survivors treated with thoracic radiation and individuals exposed to ionizing radiation in vitro
Low-dose colchicine (0.5 mg daily) effectively suppresses radiation-induced expansion of a pro-inflammatory monocyte subset by inhibiting p90RSK activation, potentially reducing vascular inflammation and cardiovascular events.
Clinical Best Practices
Utilize comprehensive immune profiling (e.g., CyTOF) to identify radiation-induced changes in monocyte subsets. Apply colchicine therapy to target specific radiation-responsive inflammatory pathways beyond NLRP3 inflammasome inhibition. Integrate cardiovascular risk assessment and management in long-term follow-up of cancer survivors receiving radiotherapy. Conduct further research to validate colchicine’s efficacy in mitigating radiation-induced cardiovascular inflammation in clinical settings. Related Resources & Content
